Colossal raises $200M Series C at a $10.2B valuation led by TWG Global

Colossal Biosciences

Colossal raised $200 million in Series C led by TWG Global, Mark Walter's and Thomas Tull's firm, valuing the company at $10.2 billion and bringing total funding to $435 million. The achievement made Colossal the first Texas startup to reach decacorn status ($10B+ valuation).

• Series C: $200 million from TWG Global and other investors.
• Post-round valuation: $10.2 billion; cumulative funding: $435 million.
• Milestone: first Texas startup to achieve decacorn status.
• Applications: de-extinction (dodo, moa, woolly mammoth, dire wolf) and genetic rescue.